Calidi Biotherapeutics, Inc. Common Stock CLDI 深 沪
等待开盘 10-23 09:30:00 美东时间
1.44
-0.080
-5.26%
华盛通- 最 高1.5099
- 今 开1.49
- 成交量 22.19万股
- 最 低 1.4101
- 昨 收 1.52
- 总市值 414.24万
- 52周最高 46.68
- 市盈率 静 --
- 换手率 7.71%
- 52周最低 1.41
- 委 比 -16.67%
- 总股本 287.67万
- 历史最高 2886.00
- 量 比 1.81
- 振 幅 6.57%
- 历史最低 1.4101
- 每 手 1
- 风险率 7.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Calidi Biotherapeutics Forms Scientific Advisory Board To Further Develop RedTail Platform And Advance CLD-401 Into Clinic
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced the formation
10-22 20:05
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
<p>Calidi Biotherapeutics announced the formation of its Scientific Advisory Board (SAB) to advance its RedTail platform and lead candidate CLD-401. The RedTail platform uses an enveloped vaccinia virus to deliver genetic medicines systemically and target metastatic sites. CLD-401 aims to replicate in tumors, induce immune responses, and express IL-15 superagonist. The SAB includes leading experts in drug development and oncology. The company is ...
10-22 12:00
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
Calidi Biotherapeutics' CEO, Eric Poma, will participate in the Oncology Venture, Innovation, and Partnering Summit to discuss the company's RedTail platform, designed to deliver genetic medicines to metastatic sites. The platform aims to protect viruses from immune clearance and enhance tumor targeting. The company's lead candidate is in IND-enabling studies for cancers like non-small cell lung and ovarian cancer. The event, held in Boston, incl...
09-29 12:00
Calidi Biotherapeutics Streamlines Leadership with Role Elimination
Calidi Biotherapeutics ( ($CLDI) ) just unveiled an update. On September 16, 20...
09-20 05:37
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Calidi Biotherapeutics Updates Presentation Disclosure
Calidi Biotherapeutics ( ($CLDI) ) just unveiled an update. On August 29, 2025,...
08-30 05:51
Calidi Biotherapeutics Completes $6.9M Public Offering
An announcement from Calidi Biotherapeutics ( ($CLDI) ) is now available. On Au...
08-23 05:47
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Calidi Biotherapeutics priced a $6 million underwritten public offering, including 1,472,764 common stock units at $2.00 each and 1,528,000 pre-funded warrant units at $1.999 each. The Series I warrants have an exercise price of $2.00 and a five-year term. Ladenburg Thalmann is the sole book-running manager, with Laidlaw as a co-manager. Calidi granted underwriters a 45-day option to purchase up to an additional 450,000 shares or warrants. The of...
08-20 13:15
Calidi files to sell 1.2M common stock units
Calidi Biotherapics (NYSE:CLDI) filed to sell 1.2M common stock units. Filing More on Calidi Biotherapeutics Seeking Alpha’s Quant Rating on Calidi Biotherapeutics Historical earnings data for Calidi ...
08-16 05:30
Calidi Biotherapeutics Announces Executive Departure Agreement
Calidi Biotherapeutics ( ($CLDI) ) has issued an update. Calidi Biotherapeutics...
08-15 05:51
